bioAffinity Technologies (NASDAQ:BIAF) Shares Set to Reverse Split on Monday, August 24th

bioAffinity Technologies, Inc. (NASDAQ:BIAF)’s stock is scheduled to reverse split on the morning of Monday, August 24th. The 1-15 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, August 23rd.

bioAffinity Technologies Trading Down 2.2%

Shares of NASDAQ BIAF traded down $0.01 during midday trading on Thursday, hitting $0.40. The stock had a trading volume of 3,329,193 shares, compared to its average volume of 4,721,966. The company has a quick ratio of 1.41, a current ratio of 1.44 and a debt-to-equity ratio of 0.14. bioAffinity Technologies has a 1-year low of $0.33 and a 1-year high of $13.50. The company has a market capitalization of $3.24 million, a price-to-earnings ratio of -0.05 and a beta of -1.05. The company has a fifty day moving average price of $0.71 and a 200 day moving average price of $1.59.

bioAffinity Technologies (NASDAQ:BIAF) last posted its earnings results on Friday, August 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.10) by $1.46. The firm had revenue of $1.51 million during the quarter, compared to the consensus estimate of $1.70 million. bioAffinity Technologies had a negative net margin of 257.30% and a negative return on equity of 220.52%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of bioAffinity Technologies from a “sell” rating to a “hold” rating in a report on Monday, August 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of bioAffinity Technologies in a research report on Monday, July 20th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Trading of bioAffinity Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC bought a new position in shares of bioAffinity Technologies during the fourth quarter valued at approximately $36,000. Scientech Research LLC bought a new stake in shares of bioAffinity Technologies in the 3rd quarter worth $49,000. Finally, J. Safra Sarasin Holding AG bought a new stake in shares of bioAffinity Technologies in the 1st quarter worth $164,000. Institutional investors own 1.64% of the company’s stock.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.